Global health insurance service company
Educate policymakers on issues related to the proposed rule: Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees; pharmacy issues related to S. 1895, the Lower Health Care Costs Act; and issues related to S. 1384, the Prescription Drug Rebate Reform Act of 2019. Monitor issues related to P.L. 111-148, the Patient Protection and Affordable Care Act, and P.L. 111-152, the Health Care and Education Reconciliation Act; H.R. 748 / S. 684, Middle Class Health Benefits Tax Repeal Act of 2019, legislation to repeal a 40 percent ACA excise tax on certain employer-sponsored health insurance plans; S. 172 / H.R. 1398, the Health Insurance Tax (HIT) Relief Act of 2019, legislation to suspend the ACA's health insurance tax (HIT) in 2020 and 2021; and S. 80, the Jobs and Premium Protection Act, full repeal of the HIT. Monitor issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act, and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions.  Educate policymakers on issues related to H.R. 861, the End Surprise Billing Act, and "No Surprises Act" Discussion Draft; issues related to 42 C.F.R. Part 2, H.R. 2062, the Overdose Prevention and Patient Safety Act, and S. 1012, the Protecting Jessica Grubb's Legacy Act; issues related to S. 1895, the Lower Health Care Costs Act, including surprise billing, and transparency and information sharing in the individual and commercial markets. Educate policymakers on issues related to the drug pricing RFI, the Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs; and proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, and closing the Part D coverage gap and direct negotiation of prescription drug prices.  Monitor issues related to Pharmacy Direct and Indirect Remuneration (DIR), including H.R. 1034 / S. 640, the Phair Pricing Act of 2019, H.R. 803, the Improving Transparency and Accuracy in Medicare Part D Spending Act, and H.R. 1035, the Improving Transparency and Accuracy in Medicare Part D Spending Act; and issues related to Medicare Part B reforms, including S. 476, the Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019; S. 657, the Drug Price Transparency Act; and H.R. 2115, the Public Disclosure of Drug Discounts Act.  Monitor H.R. 2113, Prescription Drug STAR Act.
PHA - Pharmacy TAX - Taxation/Internal Revenue Code HCR - Health Issues MMM - Medicare/Medicaid
2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE
INVARIANT LLC
740 15th St NW, Floor 5, Washington, DC, 20005, US
BENJAMIN KLEIN KATHRYN WISE BENJAMIN KLEIN KATHRYN WISE BENJAMIN KLEIN KATHRYN WISE BENJAMIN KLEIN KATHRYN WISE